Food and Drug Administration (FDA) approves the anti-migraine injection of an Indian-based pharmaceutical company for treating patients in the United States.
One of the subsidiaries of Dr.Reddy's Laboratories; Promius Pharma LLC has obtained the FDA's approval for the Zembrace SymTouch injection in January this year. Now, the company has announced that its acute migraine treatment injection Zembrace SymTouch is now commercially available in the US market.
‘Dr Reddy’s Laboratories has launched Zembrace SymTouch( sumatriptan injection) used for the treatment of migraine in the US.’
The injection is a prefilled, ready to use, single dose disposable injector. Zembrace (sumatriptan injection) is also a subcutaneous injection which can help in relieving migraine attacks rapidly.
"ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine" said Roger Cady, Associate Executive Chairman of the National Headache Foundation.
"This 3-mg, easy-to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients," added Cady.